About

About InsuSense Therapeutics

A virtual biotech based in Aarhus

InsuSense Therapeutics (IST) is a product-focused biotechnology company based on novel breakthrough science in diabetes biology, which has the potential to quantum leap to important new Type 2 diabetes therapeutics. One of the most important features in the pathophysiology of Type 2 diabetes is insulin resistance. The IP position of the company consists of different natural circulating and cellular proteins that increase insulin action at the level of target tissues. It is the aim to refine these proteins into therapeutics acting as potent and safe insulin sensitizers for type 2 diabetes.

The foundation of InsuSense comes from the pioneering science of Anders Nykjaer. Professor Nykjaer has developed the field of Vps10p-domain receptors (Sortilins). By virtue of the direct association of the Vps10p-domain with the insulin receptor, combined with the already observed effects on insulin sensitization, the discovery may have the potential to represent the next significant diabetes treatment mechanism.

InsuSense Therapeutics Goals & Strategy

IST’s vision is to bring forward novel therapeutics, based on unique scientific understanding and intellectual property of the company, offering patients superior long term management of their diabetes disease.

IST is currently pursuing this by identifying active proteins based on the naturally occurring Vps10p-domains and manufacturing these on a relevant scale.

Paul Little (CEO)

Joined Insusense as Senior VP CMC in 2014, CEO in 2018. Previous experience in biotechnology companies including 7TM Pharma A/S, Orphazyme ApS, NMD Pharma ApS and CytoKi Pharma ApS. Paul holds a Ph.D. in organic chemistry and is a Fellow of the Royal Society of Chemistry. Paul is currently an Operating Partner at Lundbeckfonden Emerge and board member of Folium Science..

Anders Nykjær (CSO)

The foundation of InsuSense comes from the pioneering science of Anders Nykjaer, M.D., Ph.D., Professor of Medical Biochemistry and Director of The Lundbeck Foundation Research Center MIND. Professor Nykjaer has developed the field of Vps10p-domain receptors (Sortilins). By virtue of the direct association of the Vps10p-domain with the insulin receptor, combined with the already observed effects on insulin sensitization, the discovery may have the potential to represent the next significant diabetes treatment mechanism.

Mads Kjølby (VP of Research)

Is our Vice President of Research at Insusense and an Assistant Professor at Aarhus University. Mads holds a Ph.D. and a Medical Doctorate and is a co-founder of Insusense.